Isabella Straumann

Isabella Straumann is a clinical researcher based in Switzerland with a focus on early‑phase human experimental pharmacology of psychedelic and entactogenic compounds. She has served as a co‑investigator and co‑author on a series of randomized, double‑blind, placebo‑controlled, crossover studies assessing acute subjective, physiological and pharmacokinetic effects of LSD, intravenous DMT, MDMA and related stereoisomers and analogues in healthy volunteers. Her work places particular emphasis on rigorous safety pharmacology, cardiovascular and autonomic monitoring, and methodological issues relevant to blinding and crossover designs in psychedelic research.

Straumann has frequently collaborated with established Swiss psychopharmacology groups and investigators, contributing to papers that compare acute profiles of multiple serotonergic hallucinogens and entactogens, examine the impact of pre‑medication (for example SSRI pre‑treatment) on psychedelic effects, and evaluate combinations or stereoisomeric formulations. Her contributions have informed safety considerations for early clinical testing and for translational discussions about therapeutic investigations in anxiety disorders and PTSD, as well as national programmes for limited medical use of psychedelic‑assisted therapies.